Product safety and compliance for medical devices in 2026
Product safety and compliance is now a lifecycle discipline
Product safety and compliance for medical devices means proving, maintaining and updating evidence that a device is safe, performs as intended and meets applicable regulatory requirements throughout its lifecycle. In 2026, that evidence is more connected than ever. The FDA’s Quality Management System Regulation, effective February 2, 2026, aligns U.S. device quality system requirements more closely with ISO 13485:2016. FDA guidance on cybersecurity and human factors, together with EU Medical Device Regulation expectations for clinical evaluation and post-market surveillance, points in the same direction: safety is not a document created at the end of development. It is a controlled system that links intended use, design inputs, risk controls, verification, validation, labeling, manufacturing, complaints, field actions and ongoing monitoring.
For more coverage of regulatory updates and device safety topics, visit the safety and compliance section.
What changed for medical device compliance in 2026
The most important U.S. change is the FDA’s Quality Management System Regulation, often called QMSR. The FDA published the final rule on February 2, 2024, and it became effective on February 2, 2026. QMSR amends 21 CFR Part 820 by incorporating ISO 13485:2016, the medical device quality management system standard, by reference. FDA materials also state that the agency began using its updated medical device manufacturer inspection compliance program on February 2, 2026, and no longer uses the older Quality System Inspection Technique for device inspections.
This does not make U.S. requirements identical to every international system. The Federal Food, Drug, and Cosmetic Act and FDA implementing regulations still control where conflicts exist. The practical direction, however, is clear. Manufacturers need a quality system that connects regulatory requirements, design and development, risk management, supplier controls, production controls, complaint handling and records in a way that can be inspected and traced.
Two other 2026 FDA documents sharpen the product safety picture. FDA’s February 2026 cybersecurity guidance describes recommendations for device design, labeling and premarket submission content for devices with cybersecurity risk. FDA’s August 2026 human factors and usability engineering guidance focuses on reducing use-related risks for intended users, uses and use environments. These guidance documents do not replace regulations, but they show how regulators expect safety evidence to address software, connected systems and real-world use conditions.
The core framework for product safety and compliance
A useful compliance framework starts with one question: what must be true for this specific device to be safe and effective in its intended use? The answer should shape classification, standards selection, design controls, clinical evidence, labeling and post-market monitoring.
| Compliance element | What it should prove | Common evidence |
|---|---|---|
| Intended use and classification | The device is regulated under the correct pathway and risk class | Intended use statement, indications, user groups, classification rationale, predicate or conformity assessment strategy |
| Quality management system | Processes are controlled and repeatable | Quality manual or equivalent documentation, procedures, training records, supplier controls, audit records, management review |
| Risk management | Hazards are identified, evaluated, controlled and monitored | Risk management plan, hazard analysis, risk control verification, residual risk evaluation, production and post-production monitoring |
| Design verification and validation | The device meets requirements and works for users in intended conditions | Design inputs, test protocols, test reports, software validation, simulated-use or clinical validation, traceability matrix |
| Labeling and UDI | Users can identify and use the device safely | Labels, instructions for use, warnings, UDI records, packaging controls, language and market-specific requirements |
| Post-market surveillance | Field experience is captured and acted on | Complaint files, adverse event reports, trend analysis, CAPA records, recall or correction records, PSUR or PMS reports where applicable |
The value of this framework is the linkage. A risk file without design traceability is weak. A design file without post-market feedback is incomplete. A complaint process that does not update risk management, labeling or CAPA becomes administrative rather than protective.
Risk management is the center of the safety file
ISO 14971:2019 is widely used as the international framework for medical device risk management. Public ISO descriptions explain that the standard covers a process for identifying hazards, estimating and evaluating associated risks, controlling those risks and monitoring control effectiveness across the device lifecycle. In practical terms, risk management should begin before detailed design decisions are locked, not after testing has already failed.
A mature risk process usually includes:
- Hazard identification across normal use, reasonably foreseeable misuse, use errors, software behavior, materials, electrical energy, sterility, biocompatibility, data security, maintenance and disposal.
- Risk estimation and evaluation using objective criteria defined before results are interpreted.
- Risk controls prioritized through inherently safe design, protective measures and safety information, rather than relying only on warnings.
- Verification of risk controls showing that controls were implemented and are effective.
- Residual risk evaluation considering whether remaining risks are acceptable in view of the device’s intended benefit.
- Production and post-production monitoring that feeds complaints, service data, literature, vigilance reports and field actions back into the risk file.
Risk management should also control the boundaries of claims. If a performance claim, clinical benefit claim or usability claim is not supported by testing, clinical data or validated analysis, it should not appear in labeling or marketing content. Overstated claims are not only a marketing issue; they can change the safety profile by encouraging unsafe use.
Human factors and cybersecurity are product safety issues
Medical device safety is no longer limited to mechanical, electrical or biological performance. FDA’s human factors guidance states that usability engineering helps manufacturers improve device design to minimize use errors and resulting harm. That matters for infusion pumps, home-use diagnostics, robotic systems, combination products, digital therapeutics and any device where user decisions can directly affect patient outcomes.
A good usability program does not simply ask whether users like the interface. It identifies critical tasks, user groups, use environments and foreseeable use errors, then tests whether intended users can complete those critical tasks safely and effectively under representative conditions. For a home-use device, that may include caregivers with limited training. For a professional device, it may include rushed clinical workflows, alarms, cleaning steps and handoffs between staff.
Cybersecurity belongs in the same safety discussion. FDA’s February 2026 cybersecurity guidance addresses devices with cybersecurity risk and discusses design, labeling and premarket submission documentation. For connected devices, unsafe outcomes may result from unauthorized access, data manipulation, unavailable functions, delayed updates or insecure interfaces with hospital networks. A credible safety file should therefore include threat modeling, secure design practices, software update planning, vulnerability handling, cybersecurity labeling and monitoring after release.
Documentation must connect requirements to evidence
Regulators and notified bodies do not assess product safety only by reading a final test summary. They expect controlled evidence. Under the EU Medical Device Regulation, manufacturers must demonstrate conformity with applicable general safety and performance requirements. The regulation also links clinical evaluation, technical documentation, risk management, post-market surveillance and, for many devices, periodic safety update reporting. See also: clinical equipment.
For manufacturers selling into multiple markets, the practical documentation challenge is not to create a separate document set for every rule. It is to maintain a traceable evidence system. A requirements traceability matrix is often the clearest organizing tool. Each user need, regulatory requirement, standard requirement and risk control should map to design inputs, verification methods, validation evidence, labeling controls and post-market monitoring where relevant.
Weak documentation often shows up as test reports without acceptance criteria, software validation that cannot be traced to hazards, labels that do not reflect residual risk controls, or supplier records that do not show how critical components are qualified. Stronger documentation includes controlled design inputs, objective test protocols, signed reports, change impact assessments, complaint trend reviews and documented decisions when a requirement is not applicable.
Post-market controls turn compliance into continuous safety
Post-market controls are where product safety and compliance either mature or fail. FDA medical device reporting requirements under 21 CFR Part 803 require manufacturers, importers and device user facilities to report certain device-related adverse events and product problems. FDA also notes an important limitation: a medical device report is not, by itself, proof that a device caused an adverse event, and passive reporting systems cannot determine incidence or causation on their own.
This limitation is why manufacturers need more than passive complaint intake. A strong post-market process combines complaint handling, service records, returns, nonconforming product data, literature review, registry information where available, supplier issues, cybersecurity vulnerability reports and trend analysis. When signals emerge, the system should determine whether to update risk management, labeling, design controls, supplier controls, CAPA or field action strategy.
In the EU, MDR Article 83 requires manufacturers to plan, establish, document, implement, maintain and update a post-market surveillance system proportionate to device risk class and device type. The same regulatory framework requires class IIa, IIb and III device manufacturers to prepare periodic safety update reports, with update frequency depending on risk class. This reinforces a broader global expectation: post-market evidence is part of the safety case, not a separate administrative file.
Practical checklist for safer compliance decisions
The following checklist can help editorial teams, regulatory teams, quality teams and product teams evaluate whether product safety and compliance evidence is moving in the right direction:
- Define intended use, indications, contraindications, user groups and use environments before selecting standards or test methods.
- Confirm the device classification and market pathway before making claims about approval, clearance or conformity.
- Build the risk management plan early and update it when design, suppliers, software, labeling or field data changes.
- Map applicable standards such as ISO 13485, ISO 14971, IEC 62366-1, IEC 62304, IEC 60601 series standards or sterilization and biocompatibility standards as relevant to the device.
- Use design verification to prove specifications were met and design validation to prove the device meets user needs and intended uses.
- Treat cybersecurity and human factors as safety disciplines when software, connectivity or user interaction can affect outcomes.
- Maintain UDI, labeling and packaging controls so the device can be identified, traced and used correctly.
- Ensure complaint handling, adverse event reporting, CAPA and field actions feed back into risk management and design controls.
- Avoid unsupported performance, safety, usability or clinical claims in public-facing content.
- Review post-market data periodically, not only after a serious complaint or recall.
Frequently asked questions
What does product safety and compliance mean for medical devices?
It means maintaining evidence that a device is designed, manufactured, labeled, monitored and updated in a way that meets applicable safety, performance and regulatory requirements. The scope includes design controls, risk management, verification, validation, clinical evidence where needed, labeling, quality system controls and post-market surveillance.
Did QMSR replace ISO 13485 certification?
No. QMSR incorporates ISO 13485:2016 into U.S. device quality system requirements, but FDA regulation and enforcement still operate under U.S. law. An ISO 13485 certificate may support a quality system strategy, but it should not be treated as automatic proof that every FDA requirement has been met.
Why are human factors part of medical device safety?
Many device hazards appear when real users interact with the product in real environments. Human factors work identifies critical tasks, foreseeable use errors and interface problems, then evaluates whether intended users can use the device safely and effectively.
How does post-market surveillance improve compliance?
Post-market surveillance captures evidence from actual use, complaints, service data, adverse event reports, literature and field actions. That evidence should be used to update risk management, labeling, design decisions and corrective actions when new safety signals appear.
What is the main mistake companies make with compliance documentation?
The most common mistake is treating documents as isolated files. A safer approach links requirements, risks, design controls, test evidence, labeling and post-market data so that each safety claim can be traced to reliable support.
